Influenza Vaccine Market Size and Growth Rate:

“The Global Influenza Vaccines Market is expected to reach US$ 6,679.8 Mn by 2025 owing to the increasing prevalence of influenza”

Influenza Vaccine Market Growth Drivers and Restraints:

The global influenza vaccines market is expected to reach US$ 6,679.8 Mn by 2025. Influenza is usually known as “flu” or “seasonal flu” triggered by influenza virus. The symptoms of influenza can be mild to severe ranging from fever to pneumonia. The global influenza vaccines market is driven by the rising prevalence of influenza. According to World Health Organization influenza affects about 3 to 5 million people globally of which there are cases of 290, 000 to 650, 000 respiratory deaths due to it. This virus generally spread through the air by coughing and sneezing or touching surfaces contaminated by a virus. WHO every year forecasts few strains which are expected to circulate in following year, that motivates pharmaceutical companies to develop influenza vaccine against these stains. Strict and mandatory government’s rule to take influenza vaccine as a preventive measure among different age group people is fueling the growth of global influenza vaccines market. Moreover reduced healthcare burden due to influenza vaccination expected to propel the market for influenza vaccine. However, Influenza vaccine made in a year may not be effective in following year owing to evolving nature of influenza virus, in healthy individual influenza vaccine is modestly effective, sometimes new strain or overlooked strain become prevalent in that season, and product recalls which may hamper the uptake and growth influenza vaccine market.

Browse More Insights of the report @ https://www.precisionbusinessinsights.com/market-reports/global-influenza-vaccine-market/

Killed or Inactivated Vaccines Dominate the Global Influenza Vaccine Market

Based on the vaccine type, global influenza vaccines market is segmented into killed or inactivated and live vaccines. Killed or inactivated vaccines dominated the global influenza vaccines market. They produce strong immune response by holding inactivated genomic component and the surface of the virus which is exposed to the antigens that are important for strong immune response. Initiation of strong and long-lasting immune response will enhance the growth of this segment.

North America Leads the Global Influenza Vaccine Market

PBI’s global influenza vaccines market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America dominated the global influenza vaccines market through 2014-2018 and expected to dominate over 2019-2025 owing to increase in prevalence of flu over there. The flu has resulted in 9.3 million to 49 million illnesses each year in the United States since 2010. It is estimated that the flu results in 31.4 million outpatient visits and more than 200,000 hospitalizations each year. Moreover, increase in research and development for new vaccines, and improved healthcare facilities are also aiding in the growth of the influenza vaccines market. Increased government support to stop the disease and to fine preventive measures is also bolstering the growth of influenza vaccines market in North America. Europe influenza vaccines market accounted for a significant share in global influenza vaccines market due to its increase in its prevalence among the European population. According to European Centre for Disease Prevention and Control around 60 % of European populations are affected with influenza virus. Moreover, development in healthcare infrastructure, and increase in disposable income in countries such as U.K, Germany etc. are also streaming the market growth in Europe region. Asia Pacific influenza vaccines market expected to grow significantly rate due to their emerging economies, increase in the prevalence of influenza virus, development of healthcare infrastructure, and technological advancements. As per Integrated Disease Surveillance Program (IDSP) under the National Centre for Disease Control a total of 38 811 laboratories confirmed cases and 2266 deaths were reported in the year 2017 in India.
Launch of newer treatment therapies, and strategic alliances are the key strategies adopted by market players

Global Influenza Vaccines market further reveals that the key player’s increasingly adopting strategies such as launch of newer treatment therapies, and long term alliance to improve market revenue share and gaining significant geographic presence across the region.

 For instance, in August 2015, CSL announced an agreement to acquire the influenza vaccines business of Novartis for US$275 million.
 Furthermore, in July 2017, Sanofi bought the vaccine biotech Protein Sciences for $750 million.
 Moreover, in October 2019, GlaxoSmithKline Biologicals got approval for their influenza virus vaccine “Fluarix Quadrivalent” by the FDA.
 Additionally, in October 2019, Seqirus Pty. Ltd. got FDA’s approval for their influenza virus vaccine “Afluria Quadrivalent”.

Key player’s profiles in the report are GlaxoSmithKline plc., Seqirus (CSL Limited), AstraZeneca, Sanofi Pasteur Inc., Sinovac Biotech Ltd., Novavax, Inc., DAIICHI SANKYO COMPANY, LIMITED., Mitsubishi Tanabe Pharma., Protein Sciences Corporation.

Avail Sample of the report for more information @ https://www.precisionbusinessinsights.com/request-sample?product_id=16918

Detailed Segmentation of Influenza Vaccine Market:

By Vaccine Type
• Killed or Inactivated Vaccine
• Live Vaccine

By Strain Type
• Trivalent Influenza Vaccine
• Quadrivaleant Influenza Vaccine

By Formulation Type
• Injections
• Nasal Sprays

By Distribution Channel
• Government Immunization programmes
• Non-Governmental Organizations (NGOs)
• Hospitals
• Clinics

Geography

o North America
o Europe
o Asia-Pacific
o Latin America
o Middle East and Africa (MEA)

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.

Contact Us:

Shreya Paul
Senior Business Development Executive
Email @ [email protected]
Call @ +1-866-598-1553
Precision Business Insights